Medifast (MED) Tops Q2 EPS by 55c ; Offers Guidance

Medifast (NYSE: MED) reported Q2 EPS of $0.92, $0.55 better than the analyst estimate of $0.37. Revenue for the quarter came in at $168.6 million versus the consensus estimate of $163.7 million.

GUIDANCE:

Medifast sees Q3 2024 EPS of $0.05-$0.07, versus the consensus of ($0.53). Medifast sees Q3 2024 revenue of $125-145 million, versus the consensus of $161.8 million.

For earnings history and earnings-related data on Medifast (MED) click here.

You May Also Be Interested In

• Concurrent Technologies (CNC:LN) PT Raised to GBP3.20 at Berenberg
• RBC Capital Reiterates Outperform Rating on Aviva PLC (AV:LN) (AVVIY)
• Morgan Stanley Downgrades Sims Metal Management Ltd. (SGM:AU) (SMUPF) to Underweight